Klaus Dugi and Boehringer Ingelheim - Free people check

(1 - 36 from 76

)

Professor Klaus Dugi | EuropaWire.eu

news.europawire.eu

Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. For media outside of the US, the UK & Canada only ...

Boehringer Ingelheim Announces Spiolto Respimat Availability in...

copdnewstoday.com

Read more about Boehringer Ingelheim's announces approvals in first European countries of Spiolto Respimat for COPD

Boehringer Ingelheim and Eli Lilly and Company announce positive...

investor.lilly.com

Klaus Dugi , Corporate Senior Vice President Medicine, Boehringer Ingelheim. " Many patients with type 2 diabetes are not meeting their blood ...

Boehringer Ingelheim and CureVac Announce Collaboration to Develop...

immuno-oncologynews.com

Read how Boehringer Ingelheim and CureVac will collaborate to develop lung cancer mRNA vaccine

Facebook: Professor Klaus Dugi, the UK Medical Boehringer Ingelheim ...

Boehringer Ingelheim and CureVac announce collaboration to develop...

www.prnewswire.com

With this we hope to be able to develop new treatments and further expand our broad pipeline in lung cancer," said Professor Klaus Dugi, Chief ...

Dabigatran and the monitoring of plasma levels in patients | The BMJ

www.bmj.com

efficacy–safety profile of dabigatran in one of the largest real-world analyses of its kind comprising 134,000 patients above 65 years. (10). Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim GmbH, Ingelheim, Germany

European Commission grants Lilly and Boehringer Ingelheim's insulin...

www.prnewswire.com

First biosimilar insulin to receive regulatory approval in the EU

Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis...

www.prnewswire.com

Dr Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim. It should be noted that in the US, telmisartan is indicated for ...

Klaus Dugi Boehringer Ingelheim (Group) [LSE]...

www.life-sciences-europe.com

Life Sciences Business Intelligence Web Portal for European countries

Klaus Dugi Boehringer Ingelheim (Group) [LSG]...

www.life-sciences-germany.com

Life Sciences Business Intelligence Web Portal for Germany, Austria and Switzerland

Insulin glargine product receives European marketing authorization

www.healio.com

Eli Lilly and Company and Boehringer Ingelheim have been granted marketing authorization by the European Commission for their insulin glargine product,...

Deputy Town Mayor Attends Boehringer Ingelheim's Ground Breaking...

bracknelltowncouncil.gov.uk

Deputy Town Mayor Attends Boehringer Ingelheim's Ground Breaking Ceremony

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...

www.ncbi.nlm.nih.gov

employee of Boehringer Ingelheim. Alexandra Marquart is an employee of Boehringer Ingelheim. Sabine Pinnetti is an employee of Boehringer Ingelheim. Hans. J. Woerle is an employee of Boehringer Ingelheim. Klaus Dugi is an ...

FDA committee unanimously recommends approval of NCBIwww.ncbi.nlm.nih.gov › pmc › articles › PMC

www.ncbi.nlm.nih.gov

... an important step in advancing care for patients with atrial fibrillation', said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.

Publications Authored by Klaus Dugi | PubFactswww.pubfacts.com › author › Klaus+Dugi

www.pubfacts.com

Diabetologia Sep 7;57(9): Epub Jun 7. Drug Metabolism and Pharmacokinetics, Development, Boehringer Ingelheim Pharma GmbH & Co.

The Epidemiological Boehringer Ingelheim Employee Study ...www.hindawi.com › journals › jobe › abs

www.hindawi.com

Kerstin Kempf,1 Stephan Martin,1 Carmen Döhring,2Klaus Dugi,3 Carolin Wolfram von Wolmar,4 Burkhard Haastert,5 and Michael ...

PharmaTelevision - Driving success by listening to the customers.

www.pharmatelevision.com

Professor Klaus Dugi, Senior Vice President Medicine at Boehringer Ingelheim talks to Fintan Walton about how they wil drive success by listening to their customers.

corporate vice president - French translation – Lingueewww.linguee.com › english-french › corporate+vice+pr...

www.linguee.com

Klaus Dugi, Corporate Vice President Medical Affairs at [...] Boehringer Ingelheim. boehringer-ingelheim.ca. boehringer-ingelheim.ca. Ces progrès sont ...

CA A1 - Crystalline form of 1´-(1-methylethyl)- 4´-[(2 ...www.google.com › patents

patents.google.com

... Boehringer Ingelheim International Gmbh, Gerd Kraemer, Hans-Juergen Martin, Gebhard Adelgoss, Klaus Dugi, Adil Duran, Peter Eickelmann, Steffen Maier, ...

Accettata domanda di AIC per nintedanib nella Fibrosi Polmonare...

www.notiziariochimicofarmaceutico.it

con esito infausto; pertanto c'è un una forte esigenza insoddisfatta di terapie efficaci che possano rallentarne la progressione – ha dichiarato Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim – L'accettazione della ...

Boehringer Ingelheim Corporation Release: OFEV® (Nintedanib*)...

www.biospace.com

• Nintedanib* slows disease progression by reducing the decline in lung function by 50% in a broad range of IPF patient types** •

Boehringer Ingelheim CureVac Partner On Lung Cancer Immunotherapy

www.bioprocessonline.com

Boehringer Ingelheim has obtained exclusive rights to develop and market CureVac’s investigational lung cancer immunotherapy. Announced in a...

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

www.biopharma-reporter.com

With this we hope to be able to develop new treatments and further expand our broad pipeline in lung cancer,” said Professor Klaus Dugi, Chief ...

FDA Grants AML Drug Volasertib Orphan Drug Designation

www.cancernetwork.com

alternative for those patients who are currently left with limited options,” said Klaus Dugi, MD, the chief medical officer at Boehringer Ingelheim, in a press release. The drug is a selective inhibitor of Polo-like kinase 1 (Plk1); ...

FT Digital Health Summit Europe

event.ft-live.com

Chief Medical Officer England. Murray Stewart Chief Medical Officer GlaxoSmithKline, Klaus Dugi Senior Vice President Medicine and Chief Medical Officer Boehringer Ingelheim ...

La Coalición Mundial del Cáncer de Pulmón y Boehringer Ingelheim...

www.boehringer-ingelheim.es

mejor –afirma el profesor Klaus Dugi, vicepresidente sénior corporativo del Departamento Médico de Boehringer Ingelheim–. La información extraída de la encuesta nos ayudará a desarrollar estrategias más eficaces para mejorar las vidas de ...

Asthma: Boehringer Ingelheim announces U.S. FDA filing ...www.boehringer-ingelheim.pt › press-release › asthma-...

www.boehringer-ingelheim.pt

Professor Klaus Dugi, Chief Medical Officer Professor Klaus Dugi, Chief Medical Officer. "We know that patients who experience asthma symptoms have about a ...

EC Approves Lilly And BI’s Insulin Glargine Product

www.outsourcedpharma.com

... and patients with another option to meet their insulin treatment needs,” said Professor Klaus Dugi, CMO of Boehringer Ingelheim.

FDA Grants Orphan Drug Designation To Boehringer Ingelheim’s...

www.outsourcedpharma.com

Klaus Dugi, CMO at Boehringer Ingelheim said, “Due to the targeted way in which volasertib works, we hope it will offer a new alternative for ...

EU approves Eli Lilly-Boehringer diabetes drugnordiclifescience.org › eu-approves-eli-lilly-boehringer-di...

nordiclifescience.org

... a holistic approach for individuals and their needs,” said Professor Klaus Dugi, chief medical officer, Boehringer Ingelheim. “We aim to bring ...

External Scientific Advisory Board- cth-mainz.dewww.unimedizin-mainz.de › management-organization

www.unimedizin-mainz.de

Klaus Dugi, Boehringer Ingelheim GmbH, Ingelheim am Rhein. Prof. Gregory Lip, University of Birmingham, Centre for Cardiovascular ...

Ventana to collaborate with Boehringer Ingelheim on the development...

www.azbio.org

... products to further advance the delivery of personalized healthcare solutions for patients,” says Klaus Dugi, Corporate Senior Vice President, ...

Volasertib, Boehringer Ingelheim´s investigational treatment of acute...

www.ksl.com

The KSL.COM Website

Boehringer Ingelheim completes patient entry for Phase III trial...

www.natap.org

Professor Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim commented: "Reducing the length of treatment time ...

Gilead and Boehringer sign license agreement for novel HIV inhibitors

www.currentpartnering.com

Dr. Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim. “While Gilead will drive the integrase inhibitors in HIV into ...

All web results to the name "Klaus Dugi"

Related search requests for Klaus Dugi

Masahiro Takeuchi

People
Forename "Klaus" (14706)
Name "Dugi" (39)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Klaus Dugi and Boehringer Ingelheim Free People Check